Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies-Reference-Cited by-同舟云学术

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

Published:2017-05-02 Issue:12 Volume:116 Page:1505-1512
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bahleda Rastislav,Grilley-Olson Juneko E,Govindan Ramaswamy,Barlesi Fabrice,Greillier Laurent,Perol Maurice,Ray-Coquard Isabelle,Strumberg Dirk,Schultheis Beate,Dy Grace K,Zalcman Gérard,Weiss Glen J,Walter Annette O,Kornacker Martin,Rajagopalan Prabhu,Henderson David,Nogai Hendrik,Ocker Matthias,Soria Jean-Charles

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201792.pdf

Reference20 articles.

1. Aleem E, Arceci RJ (2015) Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol 3: 16.

2. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14: 130–146.

3. Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A, Valius M (2014) Highlights of the latest advances in research on CDK inhibitors. Cancers 6: 2224–2242.

4. Fabre C, Gobbi M, Ezzili C, Zoubir M, Sablin MP, Small K, Im E, Shinwari N, Zhang D, Zhou H, Le Tourneau C (2014) Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol 74: 1057–1064.

5. Flaherty KT, LoRusso PM, DeMichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O’Dwyer PJ, Schwartz GK (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18: 568–576.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PICASO: Profiling Integrative Communities of Aggregated Single-cell Omics data;2024-08-29

2. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma;Cancer Letters;2024-08

3. Metal- and additive-free TfOH catalyzed chemoselective O- and S-trifluoroethylation of oxindoles, isoindolines and thio-oxindoles;Green Chemistry;2024

4. An Overview of CDK Enzyme Inhibitors in Cancer Therapy;Current Cancer Drug Targets;2023-09

5. Targeting CDK1 in cancer: mechanisms and implications;npj Precision Oncology;2023-06-13